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Abstract: Mutations are incorporated into the genomes of RNA viruses at an optimal frequency and 
altering this precise frequency has been proposed as a strategy to create live-attenuated vaccines. 
However, determining the effect of specific mutations that alter fidelity has been difficult because 
of the rapid selection of the virus population during replication. By deleting residues of the 
structural polyprotein PE2 cleavage site, E3∆56-59, in Venezuelan equine encephalitis virus (VEEV) 
TC-83 vaccine strain, non-infectious virus particles were used to assess the effect of single mutations 
on mutation frequency without the interference of selection that results from multiple replication 
cycles. Next-generation sequencing analysis revealed a significantly lower frequency of 
transversion mutations and overall mutation frequency for the fidelity mutants compared to VEEV 
TC-83 E3∆56-59. We demonstrate that deletion of the PE2 cleavage site halts virus infection while 
making the virus particles available for downstream sequencing. The conservation of the site will 
allow the evaluation of suspected fidelity mutants across alphaviruses of medical importance. 
Keywords: Alphavirus; arbovirus; fidelity mutants; mutation frequency 
 
1. Introduction 
RNA viruses are ubiquitous in nature. The success of RNA viruses is partially due to their 
strategy of generating a large number of mutations to create a cloud of closely related mutants, which 
is commonly termed a viral “quasispecies”. The viruses that comprise the quasispecies are believed 
to act co-operatively together to create a successful infection both within and outside the cell [1–3]. 
This replication strategy is not without its drawbacks as RNA viruses have evolved to exist where 
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the mutation rate is high enough to be beneficial, while the number of deleterious mutations remain 
below levels that would otherwise result in error catastrophe, the state where excessive mutations 
render proteins non-functional and can potentially lead to viral extinction. If this mutation rate is 
altered, even slightly, the resulting virus population commonly exhibits attenuation, especially in 
vivo [3–12]. Thus, an optimized mutation rate is essential for RNA virus transmission and infection. 
This inherent property of RNA viruses has allowed the generation of virus mutants that alter 
the balance of the mutational spectrum, resulting in viruses with either increased (low-fidelity) or 
decreased (high-fidelity) mutation rates. These viruses have been generated either by replicating the 
viruses under selective pressures by the use of nucleoside analogues [13–16] or by mutating the RNA-
dependent RNA polymerase (RdRp) using known mutations from related viruses [12,17]. These 
altered fidelity viruses have allowed us and other researchers to identify the effects of manipulating 
the RNA virus mutation rate, with every altered virus that has been generated showing some 
evidence of attenuation [7,12,18–22]. Conversely, as recently detailed, there have been numerous 
examples of issues with reproducibility and identifying fidelity mutants consistently [23]. While 
additional studies on the mechanistic effects of the mutations are necessary, part of the 
inconsistencies may be the result of different methods used to generate altered fidelity viruses 
coupled with the different methods used to produce virus stocks. 
Fidelity mutant viruses have the potential to be effective live-attenuated vaccines, as they result 
in attenuation of the virus and can increase immunogenicity [12,24]. However, the inconsistency of 
the results associated with fidelity mutants hampers the development of these viruses as a promising 
vaccine strategy. One major issue is that the amount of diversity generated by the virus can be masked 
by variation generated by multiple replication cycles of the virus. Additional replication cycles may 
instead measure the varying replication rates of randomly generated mutants, rather than variation 
of the original fidelity mutant. To counter this, we developed an assay that allowed us to measure 
the fidelity of a virus after just one replication cycle, thus bypassing the inherent bias of multiple 
replication cycles (Figure 1). We found that the approach described here helps control for some of the 
inconsistencies associated with virus fidelity mutants and provides a novel framework for a 
controlled measure of virus replicative fidelity.  
 
Figure 1. Schematic of mutation accumulation across several rounds of virus replication. Lines 
represent the virus genome and colored dots represent mutations. Measuring mutation frequency 
after a single round of replication provides the most accurate representation of the fidelity of the 
sequence of interest. Collecting samples from subsequent rounds of replication will inadvertently 
measure the effect of secondary mutants accumulated during replication. 
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2. Materials and Methods 
2.1. Cell Culture and Viruses 
Vero E6 (African green monkey kidney; CRL-1586) cells were sourced from the American Type 
Cell Culture Collection (ATCC; Bethesda, MD, USA). Vero cell cultures were maintained in 
Dulbecco’s minimal essential medium (DMEM) containing 10% fetal bovine serum (FBS) and 0.05 
mg/mL of gentamycin at 37°C with 5% CO2.  
Infectious clones of Venezuelan equine encephalitis virus (VEEV) TC-83 were used to create the 
PE2 cleavage site deletion mutants [25–27]. The backbone infectious clones encoded VEEV TC-83 
strain, subclones for fidelity mutants (nsP4-G14R, nsP4-A96T, and nsP4-C488Y) [12] and VEEV TC-
83 GFP (provided by Dr. Weaver from UTMB) (Figure 2A). The PE2 cleavage site residues (E3Δ56-
59) were deleted by In-Fusion HD cloning (Takara Bio; Mountain View, CA, USA) using the forward 
primer 5′-CCCCGGATCCACCGAGGAGCTGTTTAATGAG-3′ and reverse primer 5′-
TCGGTGGATCCGGGGCACTTAACAGCTG-3′ according to the manufacturer’s instructions. 
Deletions were confirmed by Sanger sequencing and the sequences of the entire plasmids were 
confirmed by Illumina sequencing. Library preparation on gDNA was performed using Illumina XT 
DNA Library kit. Paired-end sequencing was performed on an Illumina MiSeq using 500 cycle V2 
cartridge. Infectious clones were transcribed by in-vitro transcription and rescued by electroporation 
in Vero cells, in triplicate, as previously described [28].  
The envelope mutation, E1-G91D, was also cloned into the infectious clones for VEEV TC-83 and 
TC-83 GFP [29,30]. The E1-G91D mutation was made using with the In-Fusion HD cloning kit with 
the forward primer 5′-TGGGGTGACGCATATTGCTTTTGC-3′ and reverse primer 5′- 
ATATGCGTCACCCCACATGAACG-3′ according to the manufacturer’s instructions. The mutation 
in the plasmids was confirmed by Sanger sequencing and the entire plasmids were sequenced by 
Illumina sequencing as above. 
2.2. Virus Detection and Replication Assays 
Cytopathic effect (CPE) assays were performed in 12-well plates and incubated for 72 h to detect 
replicating virus as previously described [31]. Media was removed from wells and replaced with 
fresh media every 24 h. RNA was extracted from media used to rescue virus with a QIAamp RNA 
mini kit (Qiagen; Germantown, MD, USA) according to the manufacturer’s instructions. RT-PCR was 
performed with a Qiagen one-step RT-PCR kit according to the manufacturer’s instructions with 
primers 9885V (5′-TCTGGATTCAATTGCTGATCC-3′) and 10749C (5′-AGTTTTCGGCGCGAATGG-
3′) for VEEV TC-83 and TC-83 E1-G91D, or 7701V (5′-ACCTGACGTTCAAGCAACG-3′) and 8763C 
(5′-GTTCCGTGCATGTCATACC-3′) for TC-83 E3Δ56-59. 
Virus clones containing GFP insertions were transfected with Lipofectamine 2000 reagent 
(Invitrogen; Waltham, MA, USA) into Vero cell cultures in a 12-well plate according to the 
manufacturer’s instructions. After 4 h, media was removed and replaced with fresh media containing 
2% FBS. Fluorescent microscopy was used to observe the replication of viruses expressing GFP. 
2.3. Analysis of Mutation Frequency 
In vitro transcripts were used to electroporate cells in triplicate and seeded in 10 mL of media in 
T75 flasks. Media from each flask was harvested after 24 h, clarified by centrifugation, and PEG 
precipitated to concentrate virus. Concentrated virus was resuspended in PBS and stored at -80°C 
until further processing. RNA was extracted from concentrated samples with a QIAamp RNA mini 
kit (Qiagen) according to the manufacturer’s instructions. Library preparation was performed as 
previously described [12]. 
2.4. Analysis Counting All Variants (Analysis A) 
Sequence analysis was performed as previously described [12]. The quality for each 
sample/dataset was assessed using FASTQC [32]. The reads were filtered to exclude reads with 
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unknown characters and low (< 10) quality scores. Additionally, the first 16 bases of each read were 
trimmed due to nucleotide bias. The analysis was performed using VEEV strain TC-83, complete 
genome (GenBank: L01443.1), with the deleted nucleotides removed [33]. To analyze the variant 
hotspots, each sample was run through a rare-variant pipeline (available upon request). The pipeline 
first exhaustively maps each read to the reference VEEV genome without allowing mismatches, then 
unmapped reads are re-mapped with one mismatch and added to the map. The 34-base long reads 
used in the analyses were confirmed as viral sequences and not host sequences by comparison of the 
longest subsequences shared (up to one mismatch) between viral and host genomes [34]. Diversity 
per position in the viral genome was calculated by taking a ratio of the reads mapped to non-reference 
alleles and total number of reads mapped at that position. Positions in which the number of reads 
mapped with non-reference alleles was higher than reads mapped to reference alleles or coverage 
was below 100 were excluded from diversity calculations (Table S1). Mutation frequency per sample 
was calculated by summing per-position diversities and normalizing by the number of positions for 
which diversity was calculated. Positions with non-zero mutation frequency were considered to be 
variant positions. 
2.5. Analysis with Downsampled Dataset (Analysis B) 
Reads were aligned to the reference genome based on the VEEV strain TC-83, complete genome 
(GenBank: L01443.1), with the deleted nucleotides removed using the very sensitive local setting in 
Bowtie2 version 2.3.2 [35]. Bam files were sorted, indexed, processed using SAMTools Version 1.4.1 
(http://www.htslib.org/) and Picard 2.20.5 (https://broadinstitute.github.io/picard/). Files were 
downsampled to a mean coverage of 2000 reads/position. Intra-host variation was investigated using 
the DeepSNV library within R. Low-quality reads (q<10) were excluded from further analysis. 
Mutation frequency was calculated as (N-n/N) where N is equal to the total number of reads and n 
is equal to the number of reads matching the dominant genotype. 
2.6. Statistics 
All statistical analyses were performed using GraphPad Prism. Overall diversity was compared 
with one-way ANOVA and Tukey’s multiple comparisons test. 
3. Results  
3.1. Virus Replication 
The PE2 cleavage site deletion, E3∆56-59, and envelope mutation, E1-G91D, were successfully 
cloned into separate VEEV TC-83 plasmids, and viral RNA was electroporated into cells. To 
determine whether the rescued viruses were infectious, a CPE assay was performed on media 
collected at 24 h and 48 h post-electroporation from unmutated VEEV TC-83 control, TC-83 E3Δ56-
59, and TC-83 E1-G91D. Wells inoculated with harvested media from TC-83 E3Δ56-59 and TC-83 E1-
G91D electroporations were negative for CPE, while the TC-83 control wells were positive for CPE. 
These results indicate that the media collected from the TC-83 E3Δ56-59 and TC-83 E1-G91D 
electroporations is non-infectious. 
As the CPE assay alone does not indicate virus presence or replication, RT-PCR was performed 
on RNA extracted from the harvested media. The correct bands were seen with samples from the TC-
83 control as well as 24 h post-electroporation with TC-83 E3Δ56-59, and a slight band at 48 h post-
electroporation with TC-83 E3Δ56-59, corresponding to a larger release of non-infectious virus 
particles at 24 h post-electroporation. Sequencing the RT-PCR product confirmed the deletion in TC-
83 E3Δ56-59 at 24 h post-electroporation. No bands were seen for TC-83 E1-G91D samples (Figure 
2B). These results indicate that TC-83 E3Δ56-59 has replicated following electroporation and is 
present in the media, while TC-83 E1-G91D is not present in the media. 
To confirm these results and determine if TC-83 E1-G91D is replicating, TC-83 sequences 
containing a GFP reporter were transfected into cells. Fluorescent microscopy with control TC-83 
revealed replication in adjacent cells, with increased GFP expression between 24 to 48 h post-
Viruses 2020, 12, 546 5 of 11 
 
transfection (Figures 2C, F). Both TC-83 E3Δ56-59 and TC-83 E1-G91D displayed GFP expression in 
isolated cells, without the spread of virus into adjacent cells (Figures 2D, E, G, H). This indicates that 
the viral genome is replicating, but infectious virus particles are not produced.  
 
Figure 2. Mutations added to Venezuelan equine encephalitis virus (VEEV) TC-83 genome to inhibit 
infectivity. Schematic of the VEEV genome showing the location of the E3Δ56-59 and E1-G91D 
mutations and mutations suspected of altering fidelity (A). RT-PCR of media collected from VEEV 
TC-83, VEEV TC-83 E3Δ56-59 and VEEV TC-83 E1-G91D at 24 and 48 h post-electroporation (B). 
Fluorescent microscopy of Vero cells transfected with VEEV TC-83 GFP (C, F), VEEV TC-83 E3Δ56-
59 GFP (D, G) and VEEV TC-83 E1-G91D GFP (E, H). Panels C-E are 24 h post-transfection, F-H are 
48 h post-transfection. 
3.2. Overall Sequence Diversity 
The E3Δ56-59 deletion was used to aid measurement of the sequence diversity of VEEV isolates 
by preventing infectious cycles in TC-83 and mutants suspected of altering fidelity. Media from 
control and fidelity mutants was collected at 24 h post-electroporation in triplicate. The mutation 
frequency of TC-83 E3Δ56-59 was significantly higher than all the putative fidelity mutants, TC-83 
E3Δ56-59 nsP4-G14R, TC-83 E3Δ56-59 nsP4-A96T and TC-83 E3Δ56-59 nsP4-C488Y using Analysis A 
(Figure 3A). For Analysis B, the mutation frequency of TC-83 E3Δ56-59 was significantly higher than 
TC-83 E3Δ56-59 nsP4-G14R, but not significantly different to other mutants. There was no significant 
difference in the mutation frequency among fidelity mutants with either analysis method. The 
mutation frequencies observed with Analysis A were approximately three times lower than those 
observed with Analysis B for each condition. Several types of mutations were significantly more 
frequent in TC-83 E3Δ56-59 compared to the fidelity mutants (Figure 3B). All of the significantly 
different mutation types were transversions: G-C, C-A, C-G, A-C, A-T, T-A and T-G. Fidelity mutants 
did not significantly differ among mutation types.  
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Figure 3. Mutation frequency of VEEV TC-83 E3Δ56-59 mutants. Overall mutation frequency of VEEV 
TC-83 E3Δ56-59 and mutants with nsP4 mutations that alter fidelity using two methods for analysis 
(A). Frequency of specific mutation types of VEEV TC-83 E3Δ56-59 and mutants with nsP4 mutations 
that alter fidelity with Analysis A (B). Mutation frequency was compared with one-way ANOVA and 
Tukey’s multiple comparisons test. p < 0.05 is represented by *, p < 0.01 is represented by **, p < 0.001 
is represented by *** and p < 0.0001 is represented by ****. 
3.3. Sequence Diversity across the Genome 
To see if mutations accumulated at specific sequence locations, mutation frequency was viewed 
at all points across the genome. All virus isolates exhibited similar profiles for mutation frequency 
along the genome, with a large peak of diversity seen at the 3′ end of the nsP3 gene (Figure 4; Figure 
S1). Similar trends for mutation frequency along the genome were seen when comparing samples 
from Analysis A and Analysis B. Several of the most frequent mutations are found across many 
samples, with C5540A (nsP3), C5555A (nsP3) and A7653C (capsid) found at high frequencies in all 
samples (Table 1; Table S2).  
 
Figure 4. Mutation frequency of VEEV TC-83 E3Δ56-59 mutants at coding regions across the genome. 
VEEV TC-83 E3Δ56-59 (A, E), VEEV TC-83 E3Δ56-59 nsP4-G14R (B, F), VEEV TC-83 E3Δ56-59 nsP4-
A96T (C, G), and VEEV TC-83 E3Δ56-59 nsP4-C488Y (D, H). Panels A-D have been analyzed using 
Analysis A. Panels E-H have been analyzed using Analysis B. Graphs show a representative of each 
specific mutant. Blue=nsP1, red=nsP2, green=nsP3, purple=nsP4, orange=capsid, black=E3, gold=E2, 
navy blue=6k, maroon=E1. 
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Table 1. Average frequency of common mutations seen samples. Mutation frequency Analysis A 
(Analysis B). 








C5540A nsP3 0.0778 (0.1348) 0.1316 (0.2111) 0.1273 (0.2013) 0.1371 (0.2025) 
C5555A nsP3 0.0253 (0.1621) 0.0287 (0.2084) 0.0355 (0.1937) 0.0326 (0.1987) 
A7653C capsid 0.0426 (0.0549) 0.0277 (0.0350) 0.0270 (0.0371) 0.0328 (0.0367) 
4. Discussion 
Replication of RNA viruses occurs within an optimal range of mutation frequency. Disturbing 
the rate that mutations are incorporated into the virus genome is detrimental to the virus and leads 
to attenuation [8,36,37]. This is of particular interest because altering fidelity has been proposed as an 
effective method for generating live-attenuated vaccines with increased stability. While fidelity 
mutants have been reported for many viruses, interpretation of the effects of altered fidelity vary, 
especially among the studied alphavirus and poliovirus candidates [5,7–9,12,23,37,38]. Optimizing 
an assay to evaluate mutation rate with reproducible results will be a priority for vaccine 
development of fidelity mutants. This is especially challenging for alphaviruses, as the RdRp is 
unstable [23], so methods that require isolation of the RdRp to measure nucleotide incorporation rates 
are not viable. 
Ideally, only a single round of infection should be measured to determine the effect of a specific 
mutation suspected to alter fidelity. This would eliminate biased data from fitness imparted by 
random mutations that are selected during sequential infection of cells. We created a method to 
evaluate fidelity mutants by inserting previously characterized mutations that block either virus 
binding to or virus release from the host cell, E3Δ56-59 [25–27] and E1-G91D [29,30] into the structural 
proteins of the VEEV vaccine strain, TC-83. The media harvested from both TC-83 E3∆56-59 and TC-
83 E1-G91D electroporation were demonstrated to be non-infectious, while replication of the viral 
genomes was verified to have occurred following transfection. However, TC-83 E3∆56-59 provided 
a distinct advantage for downstream next-generation sequencing analysis by having virus genomes 
accessible in the media.  
These results are consistent with previous reports from alphaviruses containing either the 
E3∆56-59 or E1-G91D mutations. The E1-G91D mutation interferes with E1 trimer formation, which 
is necessary for viral assembly and release from the cell [29,30]. Deletion of E3∆56-59 eliminates the 
PE2 cleavage site and results in an unprocessed E2-E3 envelope protein. For Sindbis virus, Semliki 
Forest virus and VEEV, the uncleaved E2-E3 does not inhibit the formation of virus particles or 
budding from the cell. However, the resulting viruses are blocked at early points of infection, notably 
at binding to host cells [25,39]. Although our experiments did not isolate viral protein, the purification 
of virus RNA from the media suggests that intact virions were produced from the electroporation, as 
was seen with other alphaviruses with the E3∆56-59 deletion, including VEEV [25–27,39]. These 
characteristics meet the criteria we outlined for measuring the effects of a specific mutation on virus 
fidelity. 
To use this system of a budding, non-infectious virus to measure mutation frequency in the viral 
genome, we deleted E3∆56-59 in VEEV TC-83 plasmids containing mutations suspected to alter 
fidelity [12]. The G14R and A96T mutations were previously identified following 19 and 23 passages 
of TC-83 with 5′fluorouracil [12], while C488Y is the corresponding mutation to C483Y identified in 
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the high-fidelity chikungunya virus (CHIKV) [7]. The samples in this study containing these RdRp 
mutations were found to produce significantly lower mutation frequencies, characteristic of high-
fidelity virus, as well as having lower rates of transversion mutations.  
Previous studies with TC-83 did not evaluate the mutation frequency of the fidelity mutants 
individually. However, Kautz et al. [12] concluded that an isolate containing four mutations, 4x, did 
not show significantly different mutation frequency to TC-83, while a 3x mutant, containing nsP4-
G14R, E37G and A96T exhibited a low fidelity phenotype in Vero cells. Unlike the single RdRp 
mutants measured in this paper, the 3x and 4x isolates had significantly fewer U-C transition 
mutations, suggesting that inserting these RdRp mutations into the same TC-83 genome changed the 
types of mutations that are generated by the RdRp, which in turn lowered the overall fidelity. The 
high-fidelity C483Y mutation has only been evaluated in isolation with CHIKV but was recently 
recharacterized with next-generation sequencing across the entire genome [38]. After comparing 
mutation frequency across the genome, Riemersma et al. [38] saw no significant difference between 
wild-type CHIKV and CHIKV C483Y. Obvious differences between this and the current study are 
the virus backbone, the host cell used for replication and the use of multiple passages, and these 
factors may contribute to the discrepancies between the studies.  
Although many differences are seen between previous studies and our use of a non-infectious 
isolate, an expected difference was the value for the overall mutation frequency. The mutation 
frequencies are ~3 times higher in TC-83 E3∆56-59 than in TC-83 that was previously reported [12]. 
When compared to TC-83 3x [12] and CHIKV C483Y [38] there were ~2–4 times greater mutation 
frequencies seen in the fidelity mutants in this study. This is likely due to the lack of selection in a 
non-infectious system and tendency for mutations to be deleterious. The relatively high mutation 
frequency seen in this study may also be due to a larger proportion of virus genomes being available 
in the media. Mutations were also incorporated during in vitro transcription [40]. Although these 
should be equal across all isolates and were seen as common mutations in all isolates, they may inflate 
the overall diversity because of the limited selection in the non-infectious system. Errors from 
sequencing can also contribute to the overall mutation frequency and may be mitigated in future 
assays with the incorporation of molecular barcoding to reduce sequencing errors [41]. However, as 
the methods used here are similar to previous investigations with VEEV, sequencing errors are 
unlikely to address discrepancies in the results.  
Viewing mutations by nucleotide positions also highlights similarities and differences between 
this study and previous reports. Specific mutations were consistently seen across all samples, which 
has previously been observed [12,42]. However, it is important to note that the sites with increased 
diversity are different between this study and previously published results. Diversity hotspots in 
virus genomes are hypothesized to be driven by the host immune response [43–46]. With the lack of 
infection from E3∆56-59 mutants, there are likely minimal selective pressures to shape the viral 
genome. Therefore, we predict that the consistent mutants seen in the TC-83 E3∆56-59 isolates do not 
improve fitness, while mutations seen from previous VEEV experiments may be more advantageous 
for the virus. The increased number of mutations at the 3′ end of the nsP3 is expected, given the 
variability in this region across alphaviruses. This region, known as the hypervariable domain, has 
little conservation between closely related viruses and is able to tolerate mutations [47]. 
To accurately measure the mutation frequency of specific mutants, we attempted to alter the 
genome as minimally as possible. This will allow the assessment for fidelity of the replication 
complex as a whole. It is known that other viral proteins are crucial to virus genome replication, even 
structural proteins as demonstrated with yellow fever virus [48], so introducing any mutation may 
have an effect on mutation frequency. While the mutation to create the E3∆56-59 isolates was 
minimal, the change will prevent the dissociation of the E2-E3 proteins. Thus, deviations in mutation 
frequency caused directly by E3∆56-59 will not be accounted for in this assay. 
In conclusion, the use of the E3∆56-59 mutation in TC-83 has clear limitations based on its lack 
of infectivity. However, there is a niche to fill in accurately measuring the mutation frequency in 
potential fidelity mutants that do not have a stable RdRp. The rapid selection of mutations that 
increase fitness likely leads to the inadvertent measurement of a skewed virus population in passaged 
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samples, even if only one passage is performed. Abolishing infectivity through PE2 cleavage site 
deletion not only alleviates this issue, but allows virus to be collected from the media, bypassing the 
necessity for sample enrichment. The PE2 cleavage site is conserved among alphaviruses and has 
been shown to have similar characteristics in Sindbis virus, Semliki Forest virus and VEEV [25–27], 
so this method is likely useful for other emerging or important alphaviruses such as CHIKV, Mayaro, 
eastern equine encephalitis, o’nyong’nyong and Ross River viruses. Future research will be 
performed to examine this. Overall, our method has provided a better understanding of how and to 
what degree specific mutations alter fidelity, which will be important to aid rational design of live-
attenuated vaccines that rely on altered mutation frequency. 
Supplementary Materials: The following are available online at www.mdpi.com/1999-4915/12/5/546/s1, Figure 
S1: Mutation frequency of VEEV TC-83 E356-59 mutants at coding regions across the genome, Table S1: 
Average reads per sample for Analysis A, Table S2: Most frequent mutations for each sample for Analysis A.  
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